This dual information (genotype status and protein expression) may be particularly useful in identifying individuals at higher or lower risk and guiding their inclusion in prevention trials or early treatment strategies, aligning with the current AD prevention goals strategy [66–69], and supporting efforts to personalize interventions based on ApoE4 levels in APOE ε4 carriers [70]. Here, APOE is linked to Alzheimer disease.